Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB054329 in advanced malignancies
NCT02431260Phase 2Terminated
- Sponsor
- Incyte
- Start
- Apr 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of INCB-054329 in solid tumor, lymphoma, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Incyte. Started Apr 2015; status: terminated.
02
Drugs
INCB-054329
03
Conditions
solid tumorlymphomaacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT02431260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431260.